ERBB2 and neoplasm: Researchers have also engineered a bispecific CAR combining a HER2-binding scFv and an IL13Rα2-binding IL-13 mutein (Figure 2B), which effectively reduces antigen escape and enhances T cell anti-tumor activity (31).